Estimating the Cost-effectiveness of Detecting Cases of Chronic Hepatitis C Infection on Reception into Prison
Overview
Authors
Affiliations
Background: In England and Wales where less than 1% of the population are Injecting drug users (IDUs), 97% of HCV reports are attributed to injecting drug use. As over 60% of the IDU population will have been imprisoned by the age of 30 years, prison may provide a good location in which to offer HCV screening and treatment. The aim of this work is to examine the cost effectiveness of a number of alternative HCV case-finding strategies on prison reception
Methods: A decision analysis model embedded in a model of the flow of IDUs through prison was used to estimate the cost effectiveness of a number of alternative case-finding strategies. The model estimates the average cost of identifying a new case of HCV from the perspective of the health care provider and how these estimates may evolve over time.
Results: The results suggest that administering verbal screening for a past positive HCV test and for ever having engaged in illicit drug use prior to the administering of ELISA and PCR tests can have a significant impact on the cost effectiveness of HCV case-finding strategies on prison reception; the discounted cost in 2017 being pound2,102 per new HCV case detected compared to pound3,107 when no verbal screening is employed.
Conclusion: The work here demonstrates the importance of targeting those individuals that have ever engaged in illicit drug use for HCV testing in prisons, these individuals can then be targeted for future intervention measures such as treatment or monitored to prevent future transmission.
Kiss-Farina E, Esio-Bassey C, Plugge E, De Viggiani N Epidemiol Infect. 2024; 152:e159.
PMID: 39635854 PMC: 11626460. DOI: 10.1017/S0950268824001419.
Edmunds B, Miller E, Tsourtos G BMC Public Health. 2019; 19(1):527.
PMID: 31068170 PMC: 6505114. DOI: 10.1186/s12889-019-6847-5.
Tavoschi L, Vroling H, Madeddu G, Babudieri S, Monarca R, Vonk Noordegraaf-Schouten M Epidemiol Rev. 2018; 40(1):105-120.
PMID: 29648594 PMC: 5982719. DOI: 10.1093/epirev/mxy001.
Economic evaluation of HCV testing approaches in low and middle income countries.
Morgan J, Servidone M, Easterbrook P, Linas B BMC Infect Dis. 2017; 17(Suppl 1):697.
PMID: 29143681 PMC: 5688403. DOI: 10.1186/s12879-017-2779-9.
Cost-effectiveness of screening for hepatitis C virus: a systematic review of economic evaluations.
Coward S, Leggett L, Kaplan G, Clement F BMJ Open. 2016; 6(9):e011821.
PMID: 27601496 PMC: 5020747. DOI: 10.1136/bmjopen-2016-011821.